1364326--1/5/2010--Pure_Pharmaceuticals

related topics

{product, candidate, development}

{stock, price, share}

{product, liability, claim}

{operation, natural, condition}

{personnel, key, retain}

{interest, director, officer}

{acquisition, growth, future}

{product, market, service}

{control, financial, internal}

{operation, international, foreign}

{stock, price, operating}

{competitive, industry, competition}

{customer, product, revenue}

As a development-stage company, we have a very limited operating history on which to base an evaluation of our prospects and our business plan has not been tested. We expect to incur significant losses into the foreseeable future. We expect to face competition from a number of companies, some of which have greater financial and other resources than we do. We may experience difficulty raising additional capital, which could result in the failure of our business. We have a going concern opinion from our auditors, indicating the possibility that we may not be able to continue to operate without adequate financing. If sales of our "third-party MFAs", including Oxytetracycline, do not gain market acceptance it is unlikely that we will become profitable. The manufacturers of identified MFAs will be located overseas. Disruptions or delays in manufacturing or transporting the MFAs from overseas could adversely affect our business. The price of inputs for animal feed (e.g. corn) for animal feed has increased significantly in cost. This may hamper the ability of farmers to accept additional "cost risk" which may materially adversely affect our business. Failure to obtain FDA approval to market our products in the United States may materially adversely affect our business. Even if we receive FDA approval, our identified MFA products may not be commercially viable. The Company may be unable to proceed with its current business plan if it is unable to obtain required regulatory approvals Legislative and regulatory developments relating to the use of antibiotics in MFAs may hamper our operations and ability to generate revenue. We may incur substantial liabilities in relation to product-liability lawsuits. Potential adverse effects on human health linked to the raising or consumption of food-producing animals that utilize MFAs could result in a decrease in our sales. We may be adversely affected by price competition and the extension of patent exclusivity. Additional capital raised through the sale of share capital will cause dilution to our existing shareholders. If an active trading market for our common stock does not develop, shareholders may be unable to sell their shares. Trading on the OTC Bulletin may be volatile and sporadic, which could depress the market price of our common stock and make it difficult for shareholders to sell their shares. We are subject to penny stock rules and shareholders therefore may find it more difficult to sell their shares. We could terminate our SEC Registration, which could cause our Common Stock to be de-listed from the OTC Bulletin Board. We may not be able to enter into manufacturing agreements or other collaborative agreements on terms acceptable to us, if at all, which failure would materially and adversely affect our business. Our revenues will be dependent on the continued operation of our suppliers. Any disruption of these supply sources will have a materially adverse effect on our business Many of the third parties with whom we will conduct business may depend on government approvals, and the failure to maintain these approvals could affect the supply and delivery of the identified MFAs to us or affect the promotion, distribution or sale of the identified MFAs. The costs of producing the identified MFAs can be subject to price fluctuations, which may adversely effect our operations and financial condition Rapid technological change in our competitive marketplace may render our proposed products obsolete or diminish our ability to compete. We must hire and retain skilled employees or consultants and will be subject to high labor costs and related increased employment expenses. If we are unable to hire additional qualified personnel or consultants, our ability to continue the business may be harmed. Our Business plan depends upon the successful execution of collaborative arrangements on the part of third-parties who are outside our control. Because our directors own approximately 47.6% of our outstanding shares of common stock, they could make and control corporate decisions that may be disadvantageous to other shareholders. We may not successfully manage our objectives which could prevent achievement of our business plan and adversely affect our business We are dependent on key personnel, the loss of any of whom would likely have an adverse effect on our business Because our president and secretary have other business interests, they may not be able or willing to devote a sufficient amount of time to our business operations, which could result in an adverse effect on our business Currency exchange rate fluctuations may adversely affect the financial position of our Company

Full 10-K form ▸

1364326--1/5/2010--Pure_Pharmaceuticals_CORP